Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 11/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15511515 | 1.00 | GPR119 (0.42) | GPR119USP2MAPK1KCNJ1PDE4D | |
| SCHEMBL15511796 | 0.88 | GPR119 (0.54) | GPR119PDE4D | |
| SCHEMBL15495656 | 0.88 | GPR119 (0.54) | GPR119PDE4D | |
| SCHEMBL15511962 | 0.87 | ACACB (0.38) | ACACB | |
| SCHEMBL15511963 | 0.87 | ACACB (0.38) | ACACB | |
| SCHEMBL15511683 | 0.87 | ACACB (0.40) | ACACB | |
| SCHEMBL15511685 | 0.87 | ACACB (0.40) | ACACB | |
| SCHEMBL15511764 | 0.86 | GPR119 (0.43) | GPR119ACACB | |
| SCHEMBL15511765 | 0.86 | GPR119 (0.43) | GPR119ACACB | |
| SCHEMBL15511322 | 0.85 | GPR119 (0.45) | GPR119USP2MAPK1KCNJ1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, SLC5A2 | GPR119 1/4885USP2 2053/4885MAPK1 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.